Read by QxMD icon Read

Liver Disease & Liver Transpl.

shared collection
10 papers 25 to 100 followers
By Xiao-Dong Zhu from Liver Cancer Institute, Fudan Univ.
Barjesh Chander Sharma, Praveen Sharma, Manish Kumar Lunia, Siddharth Srivastava, Rohit Goyal, S K Sarin
OBJECTIVES: Hepatic encephalopathy (HE) is associated with poor prognosis in cirrhosis. Drugs used in the treatment of HE are primarily directed at the reduction of the blood ammonia levels. Rifaximin and lactulose have shown to be effective in HE. We evaluated the efficacy and safety of rifaximin plus lactulose vs. lactulose alone for treatment of overt HE. METHODS: In this prospective double-blind randomized controlled trial, 120 patients with overt HE were randomized into two groups: (group A lactulose plus rifaximin 1,200 mg/day; n=63) and group B (lactulose (n=57) plus placebo)...
September 2013: American Journal of Gastroenterology
James G Orr, Tara Homer, Laura Ternent, Julia Newton, Calum J McNeil, Mark Hudson, David E J Jones
Cirrhosis has a long natural history with considerable symptomatic impacts, particularly in advancing disease. Measuring health related quality of life (HRQOL) in liver disease provides detail about the nature and extent of its effects on individuals. Understanding the drivers of impaired HRQOL can help identify targets for improvement through new treatments or health systems service delivery. Evaluation of novel therapies which target symptomatic improvement, should be done with suitable outcome measures, including HRQOL assessment...
November 2014: Journal of Hepatology
Thierry Poynard, Julien Vergniol, Yen Ngo, Juliette Foucher, Vincent Thibault, Mona Munteanu, Wassil Merrouche, Pascal Lebray, Marika Rudler, Olivier Deckmyn, Hugo Perazzo, Dominique Thabut, Vlad Ratziu, Victor de Ledinghen
BACKGROUND & AIMS: The first aim was to extend the validation of FibroTest® (FT) and transient elastography (TE) as markers of occurrence of cirrhosis without complications (F4.1), oesophageal varices (F4.2), and severe complications (F4.3) in patients with chronic hepatitis B (CHB). The second aim was to validate a previous definition of an inactive carrier based on normal FT and ActiTest® (normal-FT-AT). The third aim was to assess the long-term dynamics of fibrosis in patients with sustained virological response...
November 2014: Journal of Hepatology
Fred Poordad, Christophe Hezode, Roger Trinh, Kris V Kowdley, Stefan Zeuzem, Kosh Agarwal, Mitchell L Shiffman, Heiner Wedemeyer, Thomas Berg, Eric M Yoshida, Xavier Forns, Sandra S Lovell, Barbara Da Silva-Tillmann, Christine A Collins, Andrew L Campbell, Thomas Podsadecki, Barry Bernstein
BACKGROUND: Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis. We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the NS5A inhibitor ombitasvir (ABT-267), the nonnucleoside polymerase inhibitor dasabuvir (ABT-333), and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis...
May 22, 2014: New England Journal of Medicine
Ruma Rajbhandari, Raymond T Chung
No abstract text is available yet for this article.
July 1, 2014: Annals of Internal Medicine
Roger Chou, Tracy Dana, Christina Bougatsos, Ian Blazina, Jessi Khangura, Bernadette Zakher
BACKGROUND: In 2004, the U.S. Preventive Services Task Force (USPSTF) recommended against screening for hepatitis B virus (HBV) infection. PURPOSE: To update the 2004 USPSTF review on screening for HBV infection in adolescents and adults. DATA SOURCES: MEDLINE (through January 2014), the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and PsycINFO. STUDY SELECTION: Randomized trials of screening and treatment and observational studies of screening or the association between intermediate and clinical outcomes after antiviral therapy...
July 1, 2014: Annals of Internal Medicine
Nezam Afdhal, K Rajender Reddy, David R Nelson, Eric Lawitz, Stuart C Gordon, Eugene Schiff, Ronald Nahass, Reem Ghalib, Norman Gitlin, Robert Herring, Jacob Lalezari, Ziad H Younes, Paul J Pockros, Adrian M Di Bisceglie, Sanjeev Arora, G Mani Subramanian, Yanni Zhu, Hadas Dvory-Sobol, Jenny C Yang, Phillip S Pang, William T Symonds, John G McHutchison, Andrew J Muir, Mark Sulkowski, Paul Kwo
BACKGROUND: Effective treatment for hepatitis C virus (HCV) genotype 1 infection in patients who have not had a sustained virologic response to prior interferon-based therapy represents an unmet medical need. METHODS: We conducted a phase 3, randomized, open-label study involving patients infected with HCV genotype 1 who had not had a sustained virologic response after treatment with peginterferon and ribavirin, with or without a protease inhibitor. Patients were randomly assigned to receive the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofosbuvir in a once-daily, fixed-dose combination tablet for 12 weeks, ledipasvir-sofosbuvir plus ribavirin for 12 weeks, ledipasvir-sofosbuvir for 24 weeks, or ledipasvir-sofosbuvir plus ribavirin for 24 weeks...
April 17, 2014: New England Journal of Medicine
Ira M Jacobson, Gregory J Dore, Graham R Foster, Michael W Fried, Monica Radu, Vladimir V Rafalsky, Larysa Moroz, Antonio Craxi, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk-Mahadevan, Guy De La Rosa, Ronald Kalmeijer, Jane Scott, Rekha Sinha, Maria Beumont-Mauviel
BACKGROUND: Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens have a high pill burden and are associated with increased rates and severity of adverse events, such as anaemia and rash. The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection...
August 2, 2014: Lancet
Nathan M Bass, Kevin D Mullen, Arun Sanyal, Fred Poordad, Guy Neff, Carroll B Leevy, Samuel Sigal, Muhammad Y Sheikh, Kimberly Beavers, Todd Frederick, Lewis Teperman, Donald Hillebrand, Shirley Huang, Kunal Merchant, Audrey Shaw, Enoch Bortey, William P Forbes
BACKGROUND: Hepatic encephalopathy is a chronically debilitating complication of hepatic cirrhosis. The efficacy of rifaximin, a minimally absorbed antibiotic, is well documented in the treatment of acute hepatic encephalopathy, but its efficacy for prevention of the disease has not been established. METHODS: In this randomized, double-blind, placebo-controlled trial, we randomly assigned 299 patients who were in remission from recurrent hepatic encephalopathy resulting from chronic liver disease to receive either rifaximin, at a dose of 550 mg twice daily (140 patients), or placebo (159 patients) for 6 months...
March 25, 2010: New England Journal of Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"